Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Current Atherosclerosis Reports
Published in: Current Atherosclerosis Reports 6/2011

01-12-2011 | Nutrition (William S. Harris, Section Editor)

Resveratrol in the Prevention and Treatment of Coronary Artery Disease

Authors: Louis M. Chu, Antonio D. Lassaletta, Michael P. Robich, Frank W. Sellke

Published in: Current Atherosclerosis Reports | Issue 6/2011

Login to get access

Abstract

Resveratrol is a polyphenolic compound found in red wine that is believed to be responsible for its beneficial cardiovascular effects. Extensive research in the past several decades has identified multiple mechanisms by which resveratrol modifies the cardiovascular risk factors that lead to coronary artery disease, yet translation to the clinical arena has been unexpectedly slow. In this article, we review the existing evidence regarding the beneficial effects of resveratrol and briefly discuss its potential therapeutic applications.
Literature
1.
• Roger VL, Go AS, Lloyd-Jones DM, et al. Heart disease and stroke statistics—2011 update: a report from the American Heart Association. Circulation 2011;123(4):e18–209. This article details the most recent national statistics for coronary artery disease and other cardiovascular diseases. PubMedCrossRef
2.
Minino AM, Xu J, Kochanek KD, et al. Death in the United States, 2007. NCHS Data Brief. 2009;26:1–8.PubMed
3.
Petrovski G, Gurusamy N, Das DK. Resveratrol in cardiovascular health and disease. Ann N Y Acad Sci. 2011;125:22–33.CrossRef
4.
Renaud S, de Lorgeril M. Wine, alcohol, platelets, and the French paradox for coronary heart disease. Lancet. 1992;339(8808):1523–6. This is the seminal work describing the statistics behind the French paradox.PubMedCrossRef
5.
Gaziano JM, Buring JE, Breslow JL, et al. Moderate alcohol intake, increased levels of high-density lipoprotein and its subfractions, and decreased risk of myocardial infarction. N Engl J Med. 1993;329(25):1829–34.PubMedCrossRef
6.
Jackson R, Scragg R, Beaglehole R. Alcohol consumption and risk of coronary heart disease. BMJ. 1991;303(6796):211–6.PubMedCrossRef
7.
Gronbaek M, Becker U, Johansen D, et al. Type of alcohol consumed and mortality from all causes, coronary heart disease, and cancer. Ann Intern Med. 2000;133(6):411–9.PubMed
8.
Wannamethee SG, Shaper AG. Type of alcoholic drink and risk of major coronary heart disease events and all-cause mortality. Am J Public Health. 1999;89(5):685–90.PubMedCrossRef
9.
Lazarus NB, Kaplan GA, Cohen RD, et al. Change in alcohol consumption and risk of death from all causes and from ischaemic heart disease. BMJ. 1991;303(6802):553–6.PubMedCrossRef
10.
Colditz GA, Branch LG, Lipnick RJ, et al. Moderate alcohol and decreased cardiovascular mortality in an elderly cohort. Am Heart J. 1985;109(4):886–9.PubMedCrossRef
11.
Friedman LA, Kimball AW. Coronary heart disease mortality and alcohol consumption in Framingham. Am J Epidemiol. 1986;124(3):481–9.PubMed
12.
Saremi A, Arora R. The cardiovascular implications of alcohol and red wine. Am J Ther. 2008;15(3):265–77.PubMedCrossRef
13.
Berliner JA, Navab M, Fogelman AM, et al. Atherosclerosis: basic mechanisms. Oxidation, inflammation, and genetics. Circulation. 1995;91(9):2488–96.PubMed
14.
•• Do GM, Kwon EY, Kim HJ, et al. Long-term effects of resveratrol supplementation on suppression of atherogenic lesion formation and cholesterol synthesis in apo E-deficient mice. Biochem Biophys Res Commun. 2008;374(1):55–9. This work elegantly summarized the effects of resveratrol on serum cholesterol and its components, and relates those effects to pathologic findings. PubMedCrossRef
15.
Rocha KK, Souza GA, Ebaid GX, et al. Resveratrol toxicity: effects on risk factors for atherosclerosis and hepatic oxidative stress in standard and high-fat diets. Food Chem Toxicol. 2009;47(6):1362–7.PubMedCrossRef
16.
•• Robich M, Osipov R, Nezafat R, et al. Resveratrol improves myocardial perfusion in a swine model of hypercholesterolemia and chronic myocardial ischemia. Circulation 2010;122(11 Suppl):S142–9. This is the only work to date investigating the effects of resveratrol supplementation on angiogenesis and myocardial perfusion in the setting of ongoing myocardial ischemia.PubMedCrossRef
17.
• Cho IJ, Ahn JY, Kim S, et al. Resveratrol attenuates the expression of HMG-CoA reductase mRNA in hamsters. Biochem Biophys Res Commun. 2008;367(1):190–4. This article suggests a possible mechanism for many of the beneficial effects of resveratrol.PubMedCrossRef
18.
Wang Z, Zou J, Cao K, et al. Dealcoholized red wine containing known amounts of resveratrol suppresses atherosclerosis in hypercholesterolemic rabbits without affecting plasma lipid levels. Int J Mol Med. 2005;16(4):533–40.PubMed
19.
Wilson T, Knight TJ, Beitz DC, et al. Resveratrol promotes atherosclerosis in hypercholesterolemic rabbits. Life Sci. 1996;59(1):PL 15–21.CrossRef
20.
21.
Shih DM, Xia YR, Wang XP, et al. Combined serum paraoxonase knockout/apolipoprotein E knockout mice exhibit increased lipoprotein oxidation and atherosclerosis. J Biol Chem. 2000;275(23):17527–35.PubMedCrossRef
22.
Sviridov D, Nestel P. Dynamics of reverse cholesterol transport: protection against atherosclerosis. Atherosclerosis. 2002;161(2):245–54.PubMedCrossRef
23.
Berrougui H, Grenier G, Loued S, et al. A new insight into resveratrol as an atheroprotective compound: inhibition of lipid peroxidation and enhancement of cholesterol efflux. Atherosclerosis. 2009;207(2):420–7.PubMedCrossRef
24.
Li Y, Cao Z, Zhu H. Upregulation of endogenous antioxidants and phase 2 enzymes by the red wine polyphenol, resveratrol in cultured aortic smooth muscle cells leads to cytoprotection against oxidative and electrophilic stress. Pharmacol Res. 2006;53(1):6–15.PubMedCrossRef
25.
• Deng YH, Alex D, Huang HQ, et al. Inhibition of TNF-α-mediated endothelial cell-monocyte cell adhesion and adhesion molecules expression by the resveratrol derivative, trans-3,5,4′-trimethoxystilbene. Phytother Res. 2011;25(3):451–7. This is an elegant study showing the effects of resveratrol on monocyte recruitment and activation.PubMed
26.
Zhong M, Cheng GF, Wang WJ, et al. Inhibitory effect of resveratrol on interleukin 6 release by stimulated peritoneal macrophages of mice. Phytomedicine. 1999;6(2):79–84.PubMedCrossRef
27.
Chung EY, Kim BH, Hong JT, et al. Resveratrol down-regulates interferon-γ-inducible inflammatory genes in macrophages: molecular mechanism via decreased STAT-1 activation. J Nutr Biochem. 2010(Epub ahead of print).
28.
Park DW, Baek K, Kim JR, et al. Resveratrol inhibits foam cell formation via NADPH oxidase 1-mediated reactive oxygen species and monocyte chemotactic protein-1. Exp Mol Med. 2009;41(3):171–9.PubMedCrossRef
29.
Venkatesan B, Valente AJ, Reddy VS, et al. Resveratrol blocks interleukin-18-EMMPRIN cross-regulation and smooth muscle cell migration. Am J Physiol Heart Circ Physiol. 2009;297(2):H874–86.PubMedCrossRef
30.
Ekshyyan VP, Hebert VY, Khandelwal A, et al. Resveratrol inhibits rat aortic vascular smooth muscle cell proliferation via estrogen receptor dependent nitric oxide production. J Cardiovasc Pharmacol. 2007;50(1):83–93.PubMedCrossRef
31.
Mizutani K, Ikeda K, Yamori Y. Resveratrol inhibits AGEs-induced proliferation and collagen synthesis activity in vascular smooth muscle cells from stroke-prone spontaneously hypertensive rats. Biochem Biophys Res Commun. 2000;274(1):61–7.PubMedCrossRef
32.
Li L, Gao P, Zhang H, et al. SIRT1 inhibits angiotensin II-induced vascular smooth muscle cell hypertrophy. Acta Biochim Biophys Sin (Shanghai). 2011;43(2):103–9.CrossRef
33.
Schroecksnadel K, Winkler C, Wirleitner B, et al. Anti-inflammatory compound resveratrol suppresses homocysteine formation in stimulated human peripheral blood mononuclear cells in vitro. Clin Chem Lab Med. 2005;43(10):1084–8.PubMedCrossRef
34.
Olas B, Wachowicz B, Saluk-Juszczak J, et al. Effect of resveratrol, a natural polyphenolic compound, on platelet activation induced by endotoxin or thrombin. Thromb Res. 2002;107(3–4):141–5.PubMedCrossRef
35.
Yang Y, Wang X, Zhang L, et al. Inhibitory effects of resveratrol on platelet activation inducded by thromboxane a(2) receptor agonist in human platelets. Am J Chin Med. 2011;39(1):145–59.PubMedCrossRef
36.
• Lin KH, Hsiao G, Shih CM, et al. Mechanisms of resveratrol-induced platelet apoptosis. Cardiovasc Res. 2009;83(3):575–85. This article reports an unexpected and interesting effect of resveratrol on platelets.PubMedCrossRef
37.
Boodhwani M, Sodha NR, Mieno S, et al. Functional, cellular, and molecular characterization of the angiogenic response to chronic myocardial ischemia in diabetes. Circulation. 2007;116(11 Suppl):I31–7.PubMed
38.
Gnoni GV, Paglialonga G. Resveratrol inhibits fatty acid and triacylglycerol synthesis in rat hepatocytes. Eur J Clin Invest. 2009;39(3):211–8.PubMedCrossRef
39.
•• Kim S, Jin Y, Choi Y, et al. Resveratrol exerts anti-obesity effects via mechanisms involving down-regulation of adipogenic and inflammatory processes in mice. Biochem Pharmacol. 2011;81(11):1343–51. This study details several possible molecular mechanisms for the anti-obesity effects of resveratrol.PubMedCrossRef
40.
Dal-Pan A, Blanc S, Aujard F. Resveratrol suppresses body mass gain in a seasonal non-human primate model of obesity. BMC Physiol. 2010;10:11.PubMedCrossRef
41.
•• Fullerton HJ and Steinberg GR. SIRT1 takes a backseat to AMPK in the regulation of insulin sensitivity by resveratrol. Diabetes 2010;59(3):551–3. This is a good review of the actions of AMPK and how they may be responsible for the beneficial effects of resveratrol.PubMedCrossRef
42.
Franco OH, Peeters A, Bonneux L, et al. Blood pressure in adulthood and life expectancy with cardiovascular disease in men and women: life course analysis. Hypertension. 2005;46(2):280–6.PubMedCrossRef
43.
Rivera L, Moron R, Zarzuelo A, et al. Long-term resveratrol administration reduces metabolic disturbances and lowers blood pressure in obese Zucker rats. Biochem Pharmacol. 2009;77(6):1053–63.PubMedCrossRef
44.
Behbahani J, Thandapilly SJ, Louis XL, et al. Resveratrol and small artery compliance and remodeling in the spontaneously hypertensive rat. Am J Hypertens. 2010;23(12):1273–8.PubMedCrossRef
45.
•• Mukhopadhyay P, Mukherjee S, Ahsan K, et al. Restoration of altered microRNA expression in the ischemic heart with resveratrol. PLoS One. 2010;5(12):e15705. This is one of the few studies examining the protective effects of resveratrol against ischemia-reperfusion injury, and it reports a unique mechanism for these effects.PubMedCrossRef
46.
Hung LM, Su MJ, Chen JK. Resveratrol protects myocardial ischemia-reperfusion injury through both NO-dependent and NO-independent mechanisms. Free Radic Biol Med. 2004;36(6):774–81.PubMedCrossRef
47.
Robich MP, Osipov RM, Chu LM, et al. Resveratrol modifies risk factors for coronary artery disease in swine with metabolic syndrome and myocardial ischemia. Eur J Pharmacol. 2011;664:45–53.PubMedCrossRef
48.
•• Patel KR, Scott E, Brown VA, et al. Clinical trials of resveratrol. Ann N Y Acad Sci. 2011(1214):161–9. This is a concise and comprehensive review of the registered clinical trials of resveratrol that have been completed to date.CrossRef
49.
Brown VA, Patel KR, Viskaduraki M, et al. Repeat dose study of the cancer chemopreventive agent resveratrol in healthy volunteers: safety, pharmacokinetics, and effect on the insulin-like growth factor axis. Cancer Res. 2010;70(22):9003–11.PubMedCrossRef
50.
Kennedy DO, Wightman EL, Reay JL, et al. Effects of resveratrol on cerebral blood flow variables and cognitive performance in humans: a double-blind, placebo-controlled, crossover investigation. Am J Clin Nutr. 2010;91(6):1590–7.PubMedCrossRef
Metadata
Title
Resveratrol in the Prevention and Treatment of Coronary Artery Disease
Authors
Louis M. Chu
Antonio D. Lassaletta
Michael P. Robich
Frank W. Sellke
Publication date
01-12-2011
Publisher
Current Science Inc.
Published in
Current Atherosclerosis Reports / Issue 6/2011
Print ISSN: 1523-3804
Electronic ISSN: 1534-6242
DOI
https://doi.org/10.1007/s11883-011-0202-3

Other articles of this Issue 6/2011

Current Atherosclerosis Reports 6/2011 Go to the issue

Nutrition (William S. Harris, Section Editor)

Effects of Eicosapentaenoic Acid Versus Docosahexaenoic Acid on Serum Lipids: A Systematic Review and Meta-Analysis

Nutrition (William S. Harris, Section Editor)

Effects of Dietary Factors on Lipoprotein-Associated Phospholipase A2 (Lp-PLA2)

Erratum

Erratum to: Resveratrol in the Prevention and Treatment of Coronary Artery Disease

Nutrition (William S. Harris, Section Editor)

Chocolate and Coronary Heart Disease: A Systematic Review

Nutrition (William S. Harris, Section Editor)

Effects of Diet on High-Density Lipoprotein Cholesterol

Nutrition (William S. Harris, Section Editor)

Omega-3 Fatty Acids in Food and Pharma: The Enabling Role of Biotechnology
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits